Journal of Controlled Release· 2016Q1· Review
Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases
- 1,521citations
- Q1SCImago
- 2016year
Short summary
Nanoparticle formulations can enhance drug transport across the blood-brain barrier (BBB) for treating neurodegenerative diseases like Alzheimer's and Parkinson's.
AI-generated from the title and abstract; the full text is not read.
Key points
- The blood-brain barrier (BBB) protects the brain but is often impaired in neurodegenerative diseases.
- Even a damaged BBB poses challenges for effective drug delivery.
- Nanoparticle formulations can encapsulate therapeutic molecules.
- Targeting specific brain transport processes with NPs may enhance drug delivery across the BBB.
- This approach holds promise for treating neurodegenerative and ischemic disorders.
AI-generated from the title and abstract; the full text is not read.
Abstract
The blood-brain barrier (BBB) is a vital boundary between neural tissue and circulating blood. The BBB's unique and protective features control brain homeostasis as well as ion and molecule movement. Failure in maintaining any of these components results in the breakdown of this specialized multicellular structure and consequently promotes neuroinflammation and neurodegeneration. In several high incidence pathologies such as stroke, Alzheimer's (AD) and Parkinson's disease (PD) the BBB is impaired. However, even a damaged and more permeable BBB can pose serious challenges to drug delivery into the brain. The use of nanoparticle (NP) formulations able to encapsulate molecules with therapeutic value, while targeting specific transport processes in the brain vasculature, may enhance drug transport through the BBB in neurodegenerative/ischemic disorders and target relevant regions in the brain for regenerative processes. In this review, we will discuss BBB composition and characteristics and how these features are altered in pathology, namely in stroke, AD and PD. Additionally, factors influencing an efficient intravenous delivery of polymeric and inorganic NPs into the brain as well as NP-related delivery systems with the most promising functional outcomes will also be discussed.
The authors' abstract, as published at the source. Journal of Controlled Release, 2016 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Neurology (Neuroscience)
NeurologyNeuroscience